I search for companies that are undervalued due to fear that have strong fundamentals in order to buy long, and companies that are overvalued due to greed that have weaknesses such as poor free cash flow or an unviable business model in order to short them. As Warren Buffet recommends: buy fear and sell greed. When I find potential candidates, I research the daylights out of them and only choose the best opportunities. To give you an idea of some the stocks I’ve focused on, in the past I successfully shorted Twitter, GoPro, Garmin, TrueCar, FCX, Wayfair, Pandora and Transocean, and was successfully long Cisco, Expedia, Goodyear Tire, Facebook, Apple, Celgene and Delta. Many of those are no longer good shorts or longs. My current favorite long stock is Iconix (ICON). I was previously a consultant for executives at companies such as Fidelity Investments and Google, including the Vice-president of Sales at Google. Prior to that I owned and operated two retail stores that I sold, and before that I was a journalist. I’ve been investing for 22 years in stocks, bonds, commodities and options. I spend a lot of my free time researching investments and donate half of the gains to charity.
I am mostly a daytrader engaging in both long and short bets intraday and occasionally over the short to medium term. My focus is mostly on tech stocks and more recently the shipping and offshore drilling industry.
I am located in Germany and have worked many years as an auditor for PricewaterhouseCoopers before becoming a daytrader almost 15 years ago.
During this time I managed to successfully maneuver the burst of the dotcom bubble and the aftermath of the world trade center attacks as well as the subprime crisis.
My return on employed capital has been mostly good and at times reaches up to several 100% annually so I guess I will be around for some more years.
MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies (in partnership with Seeking Alpha). Licensed Investment Advisor. Ranked 5-star analyst on Tipranks.
Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts. The firm also operates a private pooled investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
B.S. Psychology University of Missouri-Columbia
MBA University of Missouri-Columbia
Full time investor looking to capitalize on market overreactions and looking for value where others see nothing but wreckage. Long term buys and short term trades to build wealth.
I work as a community pharmacist and I work and live in Northern Italy. My interests are not limited to: dividend and biotechnology investing. I enjoy to share my experience: I write about things where I have skin in the game.
I'm a chartered accountant by profession, hailing from India, who is also pursuing CFA. I look for investments that generate strong value in the long run, and also help investors avoid pitfalls through my analysis.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Founder of Slingshot Insights, a company that works to provide retail investors access to professional grade investment research tools not readily at their disposal. As a former analyst at a large hedge fund, I found that as I began trading individual stocks on my own, I missed the research tools available to me when I worked for a large institution. The company was born from this idea and my desire to have access to a resource like SI.
www.SlingshotInsights.com Join for free today and check out our cartoon where "Investor Man" Becomes the Smart Money (and explains what Slingshot Insights can do for your diligence process)
Prior to starting Slingshot Insights, I was an analyst at a large hedge fund where I focused on the pharmaceutical industry creating investment theses driven by primary research. I remain a very active investor in a variety of stocks.
I'm a trader who trades both short-term and long-term. I started my career as a day-trader for a trading firm, but then turned to longer time frames and went on my own to manage my portfolio.
I use technical analysis as well as fundamental analysis in my research.
Manoj Madhavan, CFA, CFP, is a Principal at Oxford Chase Advisors LLC, a Dunwoody, Georgia based Registered Investment Advisory (RIA) firm. His investment philosophy is loosely based on Warren Buffet’s principles of value investing.
Manoj was born in Tiruchirapalli (Trichy), India. He has a Bachelor's degree in Engineering from Indian Institute of Technology, Varanasi, India, a Master's degree in Engineering from Louisiana State University, Baton Rouge and an Executive MBA from Emory University, Atlanta.
Am a commercial banker for one of the largest banks out there. Probably violating some corporate policy by having a trading account. (This is a bank though that prohibits its employees from having an NCAA basketball office pool or from collecting $2 to buy Power Ball tickets.) Certainly am not a professional but do more homework on a weekly basis than I ever did in high school & college combined. Family has alot of medical professions background & learning when to listen to them & when not to is an on-going battle.
I have been a successful Private Investor in the market for the last 18 years. My focus was mostly on the Tech/Internet sector when I started, but 13-14 years ago I became extremely interested in the Gold and Silver sector as I anticipated a major bull run. My in-depth research on gold and silver companies began during 2003 or so, and it has been a consistent passion since that time. I'm familiar with their stories, their stock patterns, their highs and lows, their operations/projects, their successes and failures, their management teams and turnover at the top, and all other facets of these precious metal companies. This sector has been my singular focus since I started writing on Seeking Alpha back in 2014, as I anticipated that gold and silver would soon be bottoming out and a massive bull market would unfold. I still follow the tech/internet space and I plan to eventually jump back into that sector (2009 was a very profitable year for me as bought tech at the lows), but it's not where my attention is at the moment as I see much better opportunities in gold and silver. I believe in buying value, and not chasing the next hot stock. I use several basic investing principles, the main one being buying the balance sheet. I wait for opportunities to present themselves and then establish positions. I believe in doing your homework, and I have a very research intensive focus.
Private investment analyst and writer with an interest in companies with emerging technologies oriented towards improving healthcare, alternative investments, emerging markets, and technology.
To follow me click the "Follow" button! (Easy right?)
Kumquat Research is a college student and fund manager who has been investing for 4 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, programming, drumming, video games (developing and playing) and astronomy. Articles written and comments posted by Kumquat Research are NOT financial or investment advice, and only express his opinion. Do your own due diligence!
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) email@example.com.
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science.
Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity.
Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering.
With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.
I hold a PhD in the field of epidemiology a masters degree in public health. My undergraduate training is in policy, economics and the sciences. I have utilized my training in employment with government, academia, private industry and to further analyze the fundamentals and technicals of all manner of companies in different sectors. Specifically, I like to trade growth companies, REITS, biotechnology/ pharmaceuticals, precious metals, blue chips and small-cap companies.
Each market day I get up at 530 am and begin working/analyzing data before my day job. I focus much on current events, earnings, and developments. I also work after market hours to cover after hours developments or interesting action during the day. I aim to conduct 2 analysis per business day, which helps me stay focused on my own finances.
I have been investing for about 10 years. I also enjoy trading short expiration options, and investing in stocks with 3-20 year horizons. I enjoy writing with Seeking Alpha to share my opinion and analyses. I am a large believer in the crowd source model championed by Seeking Alpha and believe every ounce of analysis and opinion should be considered when you invest your personal finances.
I am individual investor that has been investing for his retirement for the past 40 years. During that time I have had great successes and great losses but with each win and loss I have learned something about the market and the stock I own. I do not invest for a living as my real job is as a full time Plant Manager at a local manufacturing company that makes consumer products that ship worldwide. Investing is a serious hobby for me and I spend a lot of free time doing it. I know that my wife of 34 years would say that I spend to much time at it but we will both have the opportunity to appreciate my efforts in the years ahead.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
I'm primarily a long-term small-cap investor. I'll try to respond to all comments and messages.
PREVIOUSLY NAMED "BRIDGING THE GAP" – don't worry, I'm still the same person, now just writing under my real name so people can better find me.
I am an analyst and 2017 Level III Candidate in the CFA Program that has gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
Brad Thomas is a research analyst and he currently writes weekly for Forbes and Seeking Alpha where he maintains research on many publicly-listed REITs. In addition, Thomas is the Senior Analyst at iREIT Forbes and Editor of the Forbes Real Estate Investor, a monthly subscription-based newsletter.
Thomas has also been featured in Forbes Magazine, Kiplinger’s, US News & World Report, Money, NPR, Institutional Investor, GlobeStreet, and Fox Business. He was the #1 contributing analyst on Seeking Alpha in 2014 (as ranked by TipRanks) and he is currently writing a book on the legendary investor Donald Trump.
Thomas has co-authored a book (The Intelligent REIT Investor) that is available on Amazon.
Thomas received a Bachelor of Science degree in Business/Economics from Presbyterian College where he played basketball. He resides in South Carolina with his wife and kids.
I am passionate about investing since 15 years already... and would like to share a couple of ideas with my readers.
I have an engineering background (PhD) and have worked in the industry bringing billions of dollars of manufacturing facilities up from the ground mainly holding a strategic/commercial role.
Please do your own research and due diligence prior to investing your own money. Good luck!